Analysts predict that Aurora Cannabis Inc. (NYSE:ACB – Get Rating) will announce earnings of ($0.16) per share for the current quarter, according to Zacks. Four analysts have made estimates for Aurora Cannabis’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.21). Aurora Cannabis posted earnings per share of ($0.24) in the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The business is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Aurora Cannabis will report full year earnings of ($0.66) per share for the current year, with EPS estimates ranging from ($0.74) to ($0.60). For the next financial year, analysts expect that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.62) to ($0.26). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Aurora Cannabis.
Aurora Cannabis (NYSE:ACB – Get Rating) last posted its earnings results on Thursday, February 10th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.25). Aurora Cannabis had a negative return on equity of 11.52% and a negative net margin of 167.83%. The firm had revenue of $48.07 million for the quarter, compared to the consensus estimate of $45.87 million.
A number of research firms recently commented on ACB. Cantor Fitzgerald lowered their price target on shares of Aurora Cannabis from C$10.75 to C$7.60 in a report on Friday, February 11th. CIBC lowered their price target on shares of Aurora Cannabis from C$9.25 to C$6.50 in a report on Thursday, February 3rd. Finally, Zacks Investment Research raised shares of Aurora Cannabis from a “sell” rating to a “hold” rating in a report on Monday, January 31st. Three investment analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.98.
Large investors have recently modified their holdings of the company. City State Bank purchased a new position in shares of Aurora Cannabis during the fourth quarter valued at about $40,000. Citigroup Inc. increased its position in shares of Aurora Cannabis by 684.4% during the third quarter. Citigroup Inc. now owns 6,048 shares of the company’s stock valued at $42,000 after buying an additional 5,277 shares during the period. Horan Securities Inc. purchased a new position in shares of Aurora Cannabis during the fourth quarter valued at about $54,000. PFG Advisors purchased a new position in shares of Aurora Cannabis during the fourth quarter valued at about $56,000. Finally, Spire Wealth Management increased its position in shares of Aurora Cannabis by 73.0% during the fourth quarter. Spire Wealth Management now owns 10,384 shares of the company’s stock valued at $56,000 after buying an additional 4,382 shares during the period. 15.47% of the stock is owned by hedge funds and other institutional investors.
NYSE:ACB opened at $3.03 on Wednesday. The company has a current ratio of 4.92, a quick ratio of 3.70 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $679.72 million, a PE ratio of -1.93 and a beta of 2.85. The firm’s 50 day moving average is $3.51 and its 200 day moving average is $5.02. Aurora Cannabis has a 12 month low of $2.79 and a 12 month high of $10.64.
Aurora Cannabis Company Profile (Get Rating)
Aurora Cannabis Inc produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients.
See Also
Get a free copy of the Zacks research report on Aurora Cannabis (ACB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.
Recent Comments